Jiangtang Decoction Ameliorates Diabetic Kidney Disease Through the Modulation of the Gut Microbiota
Diabetes, Metabolic Syndrome and Obesity · 2023-11 · Volume 16 · 3707-3725
DOI: 10.2147/dmso.s441457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2023-11. Verfasst von Jinni Hong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Universi…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
This study aimed to elucidate the impact of Jiangtang decoction (JTD) on diabetic kidney disease (DKD) and its association with alterations in the gut microbiota.
Methods
Using a diabetic mouse model (KK-Ay mice), daily administration of JTD for eight weeks was undertaken. Weekly measurements of body weight and blood glucose were performed, while kidney function, uremic toxins, inflammation factors, and fecal microbiota composition were assessed upon sacrifice. Ultra-structural analysis of kidney tissue was conducted to observe the pathological changes.
Results
The study findings demonstrated that JTD improve metabolism, kidney function, uremic toxins and inflammation, while also exerting a modulatory effect on the gut microbiota. Specifically, the genera Rikenella, Lachnoclostridium, and unclassified_c_Bacilli exhibited significantly increased abundance following JTD treatment, accompanied by reduced abundance of norank_f_Lachnospiraceae compared to the model group. Importantly, Rikenella and unclassified_c_Bacilli demonstrated negative correlations with urine protein levels. Lachnoclostridium and norank_f_Lachnospiraceae were positively associated with creatinine (Cr), indoxyl sulfate (IS) and interleukin (IL)-6. Moreover, norank_f_Lachnospiraceae exhibited positive associations with various indicators of DKD severity, including weight, blood glucose, urea nitrogen (UN), kidney injury molecule-1 (KIM-1) levels, trimethylamine-N-oxide (TMAO), p-cresyl sulfate (pCS), nucleotide-binding oligomerization domain (Nod)-like receptor family pyrin domain-containing 3 (NLRP3) and IL-17A production.
Conclusion
These findings suggested that JTD possess the ability to modulate the abundance of Rikenella, Lachnoclostridium, unclassified_c_Bacilli and norank_f_Lachnospiraceae within the gut microbiota. This modulation, in turn, influenced metabolic processes, kidney function, uremic toxin accumulation, and inflammation, ultimately contributing to the amelioration of DKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, People's Republic of China.
- Guangdong Provincial Institute of Geriatric, Guangzhou, Guangdong, 510080, People's Republic of China.
- Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
ORCID-Profile: Jinni Hong
Zitieren
APA
Hong, J., Fu, T., Liu, W., Du, Y., Bu, J., Wei, G., Yu, M., Lin, Y., Min, C., & Lin, D. (2023). Jiangtang Decoction Ameliorates Diabetic Kidney Disease Through the Modulation of the Gut Microbiota. Diabetes, Metabolic Syndrome and Obesity, Volume 16, 3707-3725. https://doi.org/10.2147/dmso.s441457
Vancouver
Hong J, Fu T, Liu W, Du Y, Bu J, Wei G, et al. Jiangtang Decoction Ameliorates Diabetic Kidney Disease Through the Modulation of the Gut Microbiota. Diabetes, Metabolic Syndrome and Obesity. 2023;Volume 16:3707-3725. doi:10.2147/dmso.s441457
BibTeX
@article{Hong2023,
author = {Hong, Jinni and Fu, Tingting and Liu, Weizhen and Du, Yu and Bu, Junmin and Wei, Guojian and Yu, Miao and Lin, Yanshan and Min, Cunyun and Lin, Datao},
title = {Jiangtang Decoction Ameliorates Diabetic Kidney Disease Through the Modulation of the Gut Microbiota},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2023},
volume = {Volume 16},
pages = {3707--3725},
doi = {10.2147/dmso.s441457}
}
EUVIMED